Informe de análisis del tamaño, la participación y las tendencias del mercado mundial de miomectomía: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de la miomectomía

Este mercado está impulsado por la creciente prevalencia de fibromas uterinos entre las mujeres en edad reproductiva y la creciente conciencia de las opciones quirúrgicas mínimamente invasivas. Los desarrollos recientes incluyen avances en técnicas quirúrgicas asistidas por robot e instrumentos laparoscópicos mejorados , que mejoran la precisión, reducen los tiempos de recuperación y minimizan las complicaciones. Además, las innovaciones en tecnologías de imágenes, como la ecografía y la resonancia magnética, ayudan a mejorar el diagnóstico y la planificación del tratamiento. El mercado de la miomectomía también está respaldado por la creciente defensa de los pacientes de procedimientos menos invasivos y un enfoque en la salud de la mujer, lo que genera una mayor demanda de opciones de tratamiento efectivas. En general, el mercado de la miomectomía está preparado para el crecimiento a medida que los proveedores de atención médica continúan priorizando los enfoques centrados en el paciente en el manejo de los fibromas uterinos.

Tamaño del mercado de la miomectomía

El tamaño del mercado global de miomectomía se valoró en USD 758,52 millones en 2023 y se proyecta que alcance los USD 1475,17 millones para 2031, con una CAGR del 8,67% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Tendencias del mercado de la miomectomía

“ Innovaciones en cirugía asistida por robot y métodos laparoscópicos”

El mercado de la miomectomía está experimentando tendencias significativas impulsadas por los avances en las técnicas quirúrgicas y la creciente demanda de procedimientos mínimamente invasivos por parte de los pacientes. Las innovaciones en la cirugía asistida por robot y los métodos laparoscópicos están transformando la forma en que se tratan los fibromas uterinos, ofreciendo una mayor precisión y tiempos de recuperación más rápidos. Una tendencia notable es la creciente popularidad de los procedimientos ambulatorios, que permiten a las pacientes someterse a una miomectomía y regresar a casa el mismo día, lo que minimiza las estadías en el hospital y los costos asociados. Este cambio hacia la atención ambulatoria refleja un movimiento más amplio en la industria de la salud para mejorar las experiencias de los pacientes y, al mismo tiempo, mantener altos estándares de atención. A medida que aumenta el conocimiento de estas opciones, el mercado de la miomectomía se expandirá, haciendo hincapié en soluciones efectivas y menos invasivas para el manejo de los fibromas uterinos.

Alcance del informe y segmentación del mercado de miomectomía         

Myomectomy Market Definition

Myomectomy is a surgical procedure performed to remove uterine fibroids (myomas) while preserving the uterus. It is typically recommended for women who wish to retain their fertility or avoid a hysterectomy. The procedure can be conducted through various approaches, including abdominal, laparoscopic, or hysteroscopic techniques, depending on the size, location, and number of fibroids. Myomectomy aims to alleviate symptoms associated with fibroids, such as heavy menstrual bleeding, pelvic pain, and pressure on surrounding organs, thereby improving the patient's quality of life.

Myomectomy Market Dynamics

Drivers

• Rising Prevalence of Uterine Fibroids

The rising prevalence of uterine fibroids among women of reproductive age serves as a significant market driver for myomectomy procedures. Fibroids are common benign tumors that can cause a range of symptoms, including heavy menstrual bleeding, pelvic pain, and pressure on surrounding organs. As awareness of these conditions increases, more women are seeking effective treatment options to alleviate their symptoms while preserving fertility. This growing demand for targeted interventions, such as myomectomy, is leading healthcare providers to prioritize these procedures, ultimately driving market growth. Addressing the needs of this patient population is crucial for enhancing quality of life and reproductive health.

•  Desire for Fertility Preservation

Many women choose myomectomy as a surgical option to remove uterine fibroids while preserving their uterus for potential future pregnancies. This desire for fertility preservation is a crucial factor influencing the demand for myomectomy procedures. Uterine fibroids can lead to complications during pregnancy and childbirth, prompting women to seek effective solutions that allow them to manage their symptoms without sacrificing their reproductive capabilities. As more women become aware of the benefits of myomectomy, including the ability to alleviate discomfort and retain fertility, healthcare providers are witnessing an increased interest in this procedure. This growing inclination significantly contributes to the expansion of the myomectomy market.

Opportunities

• Innovation in Minimally Invasive Surgical Techniques

Continuous innovation in minimally invasive surgical techniques, including robotic-assisted surgery and advanced laparoscopic methods, presents significant opportunities in the myomectomy market. These technologies enhance surgical precision, reduce recovery times, and minimize postoperative discomfort, making the procedures more appealing to patients. As patients increasingly prefer less invasive options that promote quicker healing and fewer complications, healthcare providers are motivated to adopt these innovative techniques. The development of user-friendly robotic systems and improved laparoscopic tools further supports this trend, potentially leading to better patient outcomes. By investing in these advancements, medical facilities can attract a larger patient population seeking effective and less invasive solutions for managing uterine fibroids.

• Increasing Public Awareness in Uterine Fibroids

Increasing public awareness about uterine fibroids and the various treatment options available can significantly drive demand for myomectomy procedures. Educational campaigns aimed at both patients and healthcare professionals are crucial in enhancing understanding of this common condition and its symptoms. By providing information on the potential complications of untreated fibroids and the benefits of timely intervention, these initiatives can encourage more women to seek diagnosis and consider myomectomy as a viable treatment option. Moreover, equipping healthcare providers with the latest knowledge on fibroid management can lead to earlier referrals and improved patient outcomes. This heightened awareness creates a fertile ground for growth in the myomectomy market.

Restraints/Challenges

• Competition from Alternative Treatments

The presence of alternative therapies, such as medication and less invasive procedures such as uterine artery embolization, poses a significant challenge to the myomectomy market. Many patients are increasingly inclined to explore these options due to their non-invasive nature and perceived lower risk profiles. Medications can offer symptom relief without the need for surgery, while uterine artery embolization provides a less invasive way to treat fibroids with shorter recovery times. This trend may lead to a decline in the number of women opting for myomectomy, as they may prioritize these alternative treatments over traditional surgical interventions. Consequently, healthcare providers must navigate this competitive landscape to promote myomectomy effectively.

• High Costs of Treatment

The financial burden associated with myomectomy can be a considerable restraint on its market growth, as the costs encompass various factors, including surgery fees, hospitalization, anesthesia, and postoperative care. For many patients, particularly those without comprehensive insurance coverage, these expenses can be overwhelming and may deter them from seeking necessary treatment. The high out-of-pocket costs may lead some women to delay surgery or opt for alternative treatments that are perceived as more affordable. This financial barrier restricts access to myomectomy, resulting in unmet medical needs and contributing to a lower rate of procedure adoption among eligible patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Myomectomy Market Scope

The market is segmented on the basis of type, product, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Robotic Myomectomy
• Abdominal Myomectomy
• Hysteroscopic Myomectomy
• Laparoscopic Myomectomy

Product

• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer
• Others

End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Medical Device Companies

Myomectomy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, product, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The North America region is at the forefront of the myomectomy market, driven by a growing patient population affected by uterine fibroids and robust medical reimbursement options. The accessibility of comprehensive healthcare coverage enables more women to seek myomectomy as an effective treatment choice. Additionally, advancements in surgical techniques and increased awareness of women's health issues further bolster the demand for myomectomy procedures in this region.

The Asia-Pacific region is poised for substantial growth in the myomectomy market from 2024 to 2031, driven by a rising number of women experiencing uterine fibroids. Increased awareness about the diagnosis and treatment options available for fibroids is fostering greater demand for surgical interventions. Additionally, the rapid modernization of healthcare infrastructure in many Asia-Pacific countries is enhancing access to advanced medical technologies and services, further supporting market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Myomectomy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Myomectomy Market Leaders Operating in the Market Are:

• Boston Scientific Corporation (U.S.)
• CooperSurgical Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Karl Storz SE (Germany)
• Richard Wolf GmbH (Germany)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Stryker (U.S.)
• CONMED Corporation (U.S.)
• Hologic, Inc. (U.S.)
• B. Braun SE (Germany)

Latest Developments in Myomectomy Market

• In October 2021, Gynesonics, a company dedicated to developing minimally invasive solutions for symptomatic uterine fibroids, announced that Dr. John Thoppil became the first physician in Texas to provide its Sonata treatment. This innovative procedure is now available to women with symptomatic uterine fibroids at his River Place OB/GYN facility in Austin, Texas. By offering this office-based solution, Dr. Thoppil aims to enhance patient care and provide an effective alternative for managing uterine fibroids
• In September 2021, Gynesonics, a company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced that the Food and Drug Administration (FDA) granted clearance for the Sonata® System 2.2. This updated system introduces significant new benefits for healthcare facilities, physicians, and patients alike. The approval underscores Gynesonics' commitment to advancing treatment options for women suffering from uterine fibroids, enhancing both the efficacy and accessibility of care
• En octubre de 2021, Hologic, Inc. adquirió Bolder Surgical, una empresa privada estadounidense reconocida por sus innovadores dispositivos quirúrgicos para el sellado de vasos sanguíneos. Esta adquisición no solo amplió la cartera quirúrgica de Hologic, sino que también mejoró su posición competitiva en el mercado de la atención médica. Al integrar las tecnologías innovadoras de Bolder Surgical, Hologic tiene como objetivo fortalecer su oferta y mejorar los resultados quirúrgicos para los pacientes.
• En agosto de 2021, Hologic, Inc., una empresa líder mundial en salud de la mujer, anunció que Anthem Blue Cross Blue Shield, el segundo plan de salud más grande de los EE. UU., revisó su póliza médica para incluir la cobertura de la ablación por radiofrecuencia (LAP-RFA). Esta actualización abarca específicamente el procedimiento Acessa (código CPT 58674) para mujeres que padecen fibromas uterinos. La decisión de ampliar la cobertura refleja un creciente reconocimiento de la necesidad de opciones de tratamiento efectivas para esta afección común, lo que en última instancia mejora el acceso a la atención para las pacientes afectadas.
• En agosto de 2020, Hologic Inc. completó la adquisición de Acessa Health Inc., una empresa privada reconocida por su enfoque en terapias mínimamente invasivas para los fibromas uterinos. Esta adquisición estratégica fortaleció la oferta de productos de Hologic en el mercado de tratamiento de fibromas, lo que le permitió brindar una gama más amplia de soluciones innovadoras. Al integrar la experiencia y las tecnologías de Acessa Health, Hologic tiene como objetivo mejorar la atención al paciente y los resultados del tratamiento para las mujeres que padecen fibromas.

SKU-63640